UK markets closed
  • FTSE 100

    6,630.52
    -20.36 (-0.31%)
     
  • FTSE 250

    20,961.31
    -334.92 (-1.57%)
     
  • AIM

    1,163.26
    -10.13 (-0.86%)
     
  • GBP/EUR

    1.1607
    +0.0010 (+0.09%)
     
  • GBP/USD

    1.3834
    -0.0060 (-0.43%)
     
  • BTC-GBP

    35,538.30
    +33.00 (+0.09%)
     
  • CMC Crypto 200

    982.93
    +39.75 (+4.21%)
     
  • S&P 500

    3,841.94
    +73.47 (+1.95%)
     
  • DOW

    31,496.30
    +572.16 (+1.85%)
     
  • CRUDE OIL

    66.28
    +2.45 (+3.84%)
     
  • GOLD FUTURES

    1,698.20
    -2.50 (-0.15%)
     
  • NIKKEI 225

    28,864.32
    -65.78 (-0.23%)
     
  • HANG SENG

    29,098.29
    -138.50 (-0.47%)
     
  • DAX

    13,920.69
    -135.65 (-0.97%)
     
  • CAC 40

    5,782.65
    -48.00 (-0.82%)
     

HAEMATO AG: Patrick Brenske to be the sole member of the Executive Board of HAEMATO AG in the future

·2-min read

HAEMATO AG / Key word(s): Personnel
HAEMATO AG: Patrick Brenske to be the sole member of the Executive Board of HAEMATO AG in the future

01-Feb-2021 / 15:56 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

February 01, 2021

HAEMATO AG

Patrick Brenske to be the sole member of the Executive Board of HAEMATO AG in the future

Patrick Brenske, member of the Executive Board of HAEMATO AG since November 30, 2020 and Head of Purchasing and Sales of the HAEMATO Group for approximately eight years until 2015, will lead HAEMATO AG as sole member of the Executive Board in the future.

Daniel Kracht, member of the Executive Board responsible for Finance and Controlling, will leave the company on 28.02.2021 at his own request after many years of successful work in order to take on new professional challenges. Mr. Kracht has built up an experienced team in the area of finance/controlling, which will be led in the future by Tom Keller, who has already been working for the HAEMATO Group in the area of finance for more than five years. The Supervisory Board thanks Mr. Kracht for his work and regrets his departure.

About the HAEMATO:

HAEMATO AG, founded in 1993, is a pharmaceutical company. The business activities focus on the growth markets of high-priced special pharmaceuticals. The focus is on therapies for cancer, HIV and other chronic diseases.

HAEMATO AG is listed on the Basic Board (Open Market) of the Frankfurt Stock Exchange.
Key figures of the HAEMATO AG share:

Subscribed capital: EUR 4,753,916
Listed class of shares: ordinary bearer shares
ISIN: DE000A289VV1
WKN: A289VV
Ticker symbol: HAEK




Contact:
HAEMATO AG, Investor Relations
Telefon: +49 (0)30 897 30 86 70
ir@haemato.ag

01-Feb-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

Language:

English

Company:

HAEMATO AG

Lilienthalstraße 5c

12529 Schönefeld

Germany

Phone:

+49 (0)30 897 30 86 70

Fax:

+49 (0)30 897 30 86 79

E-mail:

ir@haemato.ag

Internet:

www.haemato.ag

ISIN:

DE000A289VV1

WKN:

A289VV

Listed:

Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Basic Board), Hamburg, Stuttgart, Tradegate Exchange

EQS News ID:

1164874


 

End of Announcement

DGAP News Service

show this
show this